Floatz logo

MIDAZOLAM

Borderline Personality Disorder (BPD)

Joshua RosenblatSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Borderline Personality Disorder (BPD) cohort.

Asset / SponsorPhaseRating
Zelapar
Mood and Anxiety Research, Inc
Phase 3BB
TEONANACATL
University of Chicago
Phase 2B
CITALOPRAM
Columbia Northwest Pharmaceuticals
Phase 2B
LITHIUM, ELEMENTAL
Columbia Northwest Pharmaceuticals
Phase 2B
Cipralex
University of Chicago
Phase 2CCC

View all 9 →

Same molecule, other indications

MIDAZOLAM is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
75 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
75 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →